Filing Flows › Ovid Therapeutics (OVID) › Q2 2026
Ovid Therapeutics (OVID) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Ovid Therapeutics (OVID) reported revenue of $733K for the second quarter 2026 (Q2 2026), -88% from a year earlier.
Ovid Therapeutics, Q2 2026: revenue $733K (-88% year over year), net loss $15.0M, operating cash flow −$17.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $733K | — | -88% |
| Operating profit | −$15.7M | — | — |
| Net earnings | −$15.0M | -255% | — |
| Operating cash flow | −$17.6M | — | — |
What changed
Revenue was $733K in Q2 2026, down 88% year over year.
Operating costs exceeded revenue by $15.7M, an operating margin of -2141.6%. Total costs grew 45% against a revenue fall of 88%. The fastest-growing cost line was Research & development (+54%). The quarter ended with a net loss of $15.0M.
Operating cash flow was −$17.6M. Non-cash charges added back $16K of depreciation and amortization and $1.4M of share-based compensation. Working capital and other items used $4.0M.
Questions
What was Ovid Therapeutics' revenue in the second quarter 2026?
Ovid Therapeutics (OVID) reported revenue of $733K for the second quarter 2026 (Q2 2026), -88% from a year earlier.
Source: Ovid Therapeutics 10-Q on SEC EDGAR.